Document is current
Any future updates will be listed below
-
Authors
Aynaud, Marie-Ming http://orcid.org/0000-0003-1788-3180
Hernandez, J. Javier
Barutcu, Seda http://orcid.org/0000-0003-2739-4153
Braunschweig, Ulrich http://orcid.org/0000-0001-6653-0926
Chan, Kin
Pearson, Joel D.
Trcka, Daniel
Prosser, Suzanna L. http://orcid.org/0000-0001-6373-9716
Kim, Jaeyoun
Barrios-Rodiles, Miriam
Jen, Mark
Song, Siyuan
Shen, Jess
Bruce, Christine
Hazlett, Bryn
Poutanen, Susan
Attisano, Liliana http://orcid.org/0000-0003-4824-2642
Bremner, Rod http://orcid.org/0000-0001-9184-7212
Blencowe, Benjamin J. http://orcid.org/0000-0002-4461-0340
Mazzulli, Tony
Han, Hong
Pelletier, Laurence http://orcid.org/0000-0003-1171-4618
Wrana, Jeffrey L. http://orcid.org/0000-0003-0932-0644
-
Funding
Funding for this research was provided by:
University of Toronto
Krembil Foundation
- License Information
-
More Information
Article History
Received: 13 October 2020
Accepted: 5 February 2021
First Online: 3 March 2021
Competing interests
: J.L.W. is founder and CEO of iTP Biomedica Inc, which employs whole transcriptome NGS tests in cancer, and he is founder and consultant for Fibrocor LP, which is developing therapeutics for fibrotic disease. The other authors declare no competing interests.
